Foresee Pharmaceuticals Co., Ltd.

Wrapping up an exciting week at the American Thoracic Society International Conference! It was a great pleasure to present our novel first-in-class oral ALDH2 activator, FP-045, and the clinical design of our upcoming P2 PH-ILD clinical study (WINDWARD study), as well as the positive primary outcomes of the aderamastat (FP-025) Phase 2 proof-of-concept allergic asthma study, at #ATS2024 conference. Thanks to all the attendees who stopped by our posters last week! A big thanks to our dedicated team, whose hard work made this poster presentation/event a success. For more information, please visit Foresee website👉 https://lnkd.in/gw974YGP #ALDH2activator #WINDWARD #PulmonaryHypertension #InterstitialLungDisease #MMP12inhibitor #aderamastat

May is #AsthmaandAllergyAwarenessMonth! A great time to support and raise public awareness. Aiming to further advance innovative therapies, Foresee Pharmaceuticals has initiated a Phase 1 clinical trial of FP-020 in Australia with future development targeted in severe asthma and COPD. We strive to improve patients' quality of life and provide cure through innovative research. 👉 Learn more about asthma and allergies:  Asthma and Allergy Foundation of America https://lnkd.in/eK6nJdZK American Thoracic Society https://lnkd.in/dSdseyN European Respiratory Society https://www.ersnet.org/ #AsthmaAwareness #MMP12inhibitor #FP020

May is #FanconiAnemiaAwarenessMonth💙 A time to support and raise awareness for this #RareDisease. Foresee Pharmaceuticals is pleased to support the work to help improve the health, well-being and public awareness. Aiming to further advance Fanconi anemia care, Foresee Pharmaceuticals has initiated a Phase 1b/2 clinical trial in adolescent and pediatric patients with Fanconi anemia (aka FuschiA study) in the US. We strive to improve patients' quality of life and provide cure through innovative research. 👉Learn more about Fanconi anemia :  Fanconi Cancer Foundation https://lnkd.in/gp75wdB2 American Society of Hematology https://lnkd.in/gZYBp2Zk #Fanconianemia #ALDH2activator #FP045 #FuschiA

Foresee Pharmaceuticals is pleased to announce that the first subject has been dosed in its Phase 1 clinical trial of FP-020 in Australia. We are very enthusiastic about the promise of FP-020 as a best-in-class MMP-12 inhibitor, a pipeline-in-a-drug opportunity with potential for once-a-day oral dosing. Additionally, we are working diligently to build a broad franchise leveraging our multiple MMP-12 inhibitors across several therapeutic areas. Learn more👉https://lnkd.in/gT4Kuaa6 #FP020 #MMP12inhibitor #Phase1

Foresee Pharmaceuticals will be participating and presenting two posters at the 2024 American Thoracic Society International Conference, which will be held in San Diego, CA, from May 17 to 22, 2024. See you there! 📢 1st Poster Title: A Multinational Phase 2, Randomized, Double-blinded, Placebo-controlled, Multiple-dose Study to Evaluate the Safety and Efficacy of FP-045, An Aldehyde Dehydrogenase 2 Activator in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease 📌 Poster Board Number: P1360 ▶ Poster Session: A32- Bench to Bedside in ILD 📆 Date/Time: Sunday, May 19, 2024, from 11:30 AM-1:15 PM PT 📍 Location: San Diego Convention Center, Area L (Hall H, Ground Level) 📢 2nd Poster Title: Effect of aderamastat (FP-025), A Selective MMP-12 Inhibitor, on Allergen-induced Airway Responses in Subjects with House-dust Mite Allergic Mild Asthma and Blood Eosinophilia 📌 Poster Board Number: P671 ▶ Poster Session: C35- Innovative Biomarkers to Identify Allergic Inflammation 📆 Date/Time: Tuesday, May 21, 2024, from 11:30 AM-1:15 PM PT 📍 Location: San Diego Convention Center, Area F (Hall A-B2, Ground Level) To learn more👉https://lnkd.in/gNne9iXP #ATS2024 #FP045 #ALDH2activator #WINDWARD #PulmonaryHypertension #InterstitialLungDisease #MMP12inhibitor #aderamastat

Last Friday was a remarkable day for our company as we came together for an inspiring corporate event in Taipei led by our visionary Chairman/CEO, Ben Chien, and our accomplished CBO/COO, Mathieu Boudreau. During the event, we had the opportunity to delve deep into our business vision and corporate goals. Our Chairman/CEO shared inspiring insights into our strategic direction, emphasizing our dedication to driving positive change and making a meaningful impact in the industry. With a focus on expansion and value creation for our stakeholders, our CBO/COO shared impactful insights on the IP portfolio, strategy, and commercial opportunities, impling the importance of staying agile in a dynamic business landscape. Stay tuned for more updates as we embark on this exciting chapter of growth and innovation! #BusinessVision #CorporateGoals #ValueCreation

Foresee Pharmaceuticals is pleased to announce the positive safety review by the independent Data and Safety Monitoring Board (DSMB) for its Casppian Phase 3 registration study. The DSMB recommended the continuation of patient enrollment as planned. The Casppian Phase 3 study is an open-label, multicenter, multinational clinical trial to evaluate the efficacy, safety, and pharmacokinetics of Leuprolide (FP-001) 42 mg-controlled release in patients with central (Gonadotropin-Dependent) precocious puberty (CPP). Foresee’s Leuprolide injectable emulsion, 42 mg (marketed under the brand name CAMCEVI®), is currently approved for the treatment of adult patients with advanced prostate cancer and has demonstrated positive efficacy and safety results with statistically significant treatment effects in adult male patients with advanced prostate cancer.   There has been no safety concern with the use of Leuprolide (FP-001) injectable Emulsion in pediatric CPP patients. Learn more👉https://lnkd.in/gbpG-t5C #leuprolide #leuprorelin #readytouse #CentralPrecociousPuberty #Casppian

April is National #sarcoidosis Awareness Month ! Foresee Pharmaceuticals is pleased to support the work to help improve the health and raise public awareness💜 Sarcoidosis is a rare inflammatory disease that can affect many organs of the body, most commonly the lungs. The inflammation causes the formation of nodules, called granulomas, in the affected organs. We don’t know how STRONG WE ARE until being strong is the only CHOICE we have. Foresee is holding STRONG supporting Sarcoidosis patients.  Learn more about sarcoidosis, visit American Lung Association website: https://lnkd.in/gg2XWxMY And here Foundation For Sarcoidosis Research: https://lnkd.in/gv2HtGPs More information at WASOG: https://www.wasog.org/ #SarcoidosisAwareness #RareDisease #sarcoidosis

Join us in welcoming Allison McCourt to Foresee Pharmaceuticals as our Director of Alliance Management!

November 17 is World Prostate Cancer Awareness Day💙 On this important day, let's join to raise awareness about prostate cancer and emphasize the significance of early detection and timely intervention. Foresee Pharmaceuticals is proud of developing #CAMCEVI as a treatment option for men with advanced prostate cancer. CAMCEVI is currently available in the U.S.! Learn more about prostate cancer👉 Prostate Cancer Foundation https://lnkd.in/giuRy5e Learn more about CAMCEVI👉 https://lnkd.in/g55DkMyr #prostatecancerawareness #menshealth #cancersupport